Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
For example, an elegant roadmap was laid out a year ago by Karolina Kauppi and colleagues wherein they combined a data set for schizophrenia risk genes and another set of genes associated with antipsychotic drug targets.<sup>3</sup> Using this "network biology" approach, they identified four schizophrenia risk genes that were also antipsychotic drug targets (GRM3, DRD2, CHRM4, and CYP2D6); they also found several molecular targets that are not currently connected to antipsychotic drug treatment, providing researchers with some potential targets for novel therapeutics.<sup>4</sup>.
|
31340894 |
2019 |
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We divided 36 patients with schizophrenia who had undergone treatment mainly with risperidone into two groups: one with normal metabolizing activity of CYP2D6 (n = 15), and the other with lower activity of its variant, CYP2D6*10 (n = 21).
|
30870237 |
2019 |
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
There actually exists significant implication of CYP2D6 genetic polymorphisms on the metabolic kinetics of risperidone, little is known about the extent of CYP2D6 impacting human D2 and 5-HT2A receptor occupancies as well as the clinical efficacy and efficacy in schizophrenia treatment.
|
30281999 |
2018 |
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In a cohort of schizophrenia inpatients CYP2D6 metabolic activity affects mean AP daily dose only in the presence of DRD2 Taq1A polymorphic allele.
|
29930225 |
2018 |
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The frequencies for the CYP2D6*4 variant were 0.092 and 0.096 in schizophrenia and bipolar groups, respectively.
|
29921201 |
2018 |
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
So, we attempted to evaluate the association between dopamine D2 (DRD2) receptor, serotonergic (5HT2A) receptor and CYP2D6 gene polymorphisms and response to treatment with risperidone in persons with schizophrenia from North India.
|
28692863 |
2017 |
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
The authors studied the correlations between the steady-state plasma concentrations (Css) of aripiprazole and its active metabolite, dehydroaripiprazole, and those of haloperidol in 19 Japanese patients with schizophrenia, together with the effects of CYP2D6 genotypes on the steady-state kinetics of these compounds.
|
24739668 |
2014 |
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The CYP2D6 genotype in children and adolescents with schizophrenia and bipolar disorder, proved to be a good predictor for the response to atypical antipsychotics and the side effects registered.
|
25329115 |
2014 |
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia.
|
23066770 |
2012 |
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia.
|
23066770 |
2012 |
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
|
21157400 |
2011 |
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
|
21157400 |
2011 |
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated the relationship between several functional polymorphisms in genes coding for dopamine metabolism and transport enzymes (MAO-A VNTR; MAO-A 941T>G; DAT VNTR; DAT -67A/T; CYP2D6*3; CYP2D6*4; CYP2D6*5; CYP2D6*6) and the frequency of schizophrenia.
|
20041956 |
2010 |
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
We investigated the relationship between several functional polymorphisms in genes coding for dopamine metabolism and transport enzymes (MAO-A VNTR; MAO-A 941T>G; DAT VNTR; DAT -67A/T; CYP2D6*3; CYP2D6*4; CYP2D6*5; CYP2D6*6) and the frequency of schizophrenia.
|
20041956 |
2010 |
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
Xenobiotic metabolizing and transporter genes: gene-gene interactions in schizophrenia and related disorders.
|
21142916 |
2010 |
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results of this study imply the potential role of CYP2D6 genotyping in personalizing risperidone therapy in patients with schizophrenia to reduce the incidence of adverse extrapyramidal symptoms.
|
20599499 |
2010 |
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We devised a CYP2D6 genotyping strategy to analyse the South African Xhosa population and genotype a Xhosa schizophrenia cohort, as CYP2D6 metabolises many antipsychotics and antidepressants.
|
20597905 |
2010 |
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CYP2D6 poor metabolizer genotype seems not to be a determining factor of schizophrenia susceptibility in Brazilians.
|
19761369 |
2009 |
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We identified 18 PM patients with a schizophrenia spectrum diagnosis from a clinical database covering all patients who have been analyzed in an ongoing standardized CYP2D6 screening program.
|
19521114 |
2009 |
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.
|
19387994 |
2009 |
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We tested whether substance abuse disorder and suicidal behavior were associated with the CYP2D6 and CYP2C19 genotypes among patients with schizophrenia.
|
18520596 |
2008 |
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Clinical significance of a CYP2D6 poor metabolizer--a patient with schizophrenia on risperidone treatment.
|
18806696 |
2008 |
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We identified the null variants *3,*4,*5,*6,*7 and *8 of the CYP2D6 gene [encoding for cytochrome P450 (debrisoquine hydroxylase)] in a group of 84 chronic-stay psychiatric inpatients with severe schizophrenia or related disorders and receiving treatment with one or more CYP2D6 substrates for years.
|
18425996 |
2008 |
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
We identified the null variants *3,*4,*5,*6,*7 and *8 of the CYP2D6 gene [encoding for cytochrome P450 (debrisoquine hydroxylase)] in a group of 84 chronic-stay psychiatric inpatients with severe schizophrenia or related disorders and receiving treatment with one or more CYP2D6 substrates for years.
|
18425996 |
2008 |
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of the presentation was to evaluate the impact of CYP2D6 genotype on psychopathological and extrapyramidal symptoms in a group of Slovenian outpatients with schizophrenia or schizoaffective disorder in stable remission, who were receiving long-term maintenance therapy.
|
18827765 |
2008 |